Hints and tips:
Showing results for BOEHRINGER LABRATORIES, INC.
...The initial list of 10 drugs to face price negotiations includes a diabetes pill called Jardiance sold by Boehringer Ingelheim and Eli Lilly; a medicine to prevent strokes called Eliquis made by Pfizer and...
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...Drugmakers GSK and Boehringer Ingelheim are now rationing inhalers, according to Premier....
...earnings were $741m, compared with $2bn the year before, primarily due to an increase in the fair value contingent consideration for the psoriasis drug Skyrizi, part of a collaboration with German drugmaker Boehringer...
...Another company, Boehringer Ingelheim of Germany, remains in patent litigation with AbbVie and has no plans for a European launch, despite its medicine being approved for sale in the EU....
...That would have been close to the multiple of 22 times operating earnings before usual deductions used to price Sanofi’s €21.8bn asset swap with Boehringer Ingelheim last year....
...Institute for Human Data Science, which charts pharmaceutical industry trends, said the groups looking to carve out a big slice of the biosimilars market were “a mix of companies you recognise — Pfizer, Boehringer...
...Addyi was first developed as an antidepressant in the 1990s by Boehringer Ingelheim, the German pharmaceuticals group, but failed to make it through clinical trials....
...At Boehringer, Mr Neumann acknowledges the process is not always smooth....
...Mr Boehringer said it was Cleveland Research’s policy not to discuss research with the press....
...Even so, the big multinationals — under pressure to focus — have been hiving off their animal medicine arms: Novartis to Eli Lilly; Sanofi of France to Boehringer Ingelheim....
...The group forecast revenue of $2bn-$2.1bn for 2016, a significant jump, part of which stems from the added revenues it will receive from Roxane Laboratories, the business it agreed to buy from Boehringer...
...Samsung Biologics ranks third behind Lonza of Switzerland and Boehringer Ingelheim of Germany....
...Jordan-founded but UK-listed Hikma initially agreed to buy the business from Boehringer Ingelheim in July, declaring that the deal would transform its scale and position in the US....
...while Boehringer would become the second largest company in animal health....
...Sanofi last month completed a €22.8bn asset swap with Boehringer Ingelheim, which allowed the French group to trade its animal health unit and gain a new consumer-health focused business as well as a €4.7bn...
...Privately-held Boehringer, with a substantial animal health division of its own, is a better owner....
...The first was an €18bn asset swap with Boehringer Ingelheim agreed last December, which, once completed, will see Sanofi trade its animal health unit for the German group’s consumer health business....
...In December 2015, Sanofi entered talks with Boehringer Ingelheim over an €18bn asset exchange that would see the French drugmaker swap its animal health unit for the German company’s consumer health business...
...Possible buyers include Zoetis and pharma groups that still have animal health divisions: Lilly, Bayer and possibly Boehringer Ingelheim, which is privately held....
...As head of the firm’s M&A practice, Mr Cooke recently led the team advising Hikma Pharmaceuticals on its $2.65bn acquisition of Roxane from Boehringer Ingelheim, and Shire on its proposed merger with AbbVie...
...Based on 2014 revenues, the combined entity would have ranked 21st among global pharma groups with $12bn of sales, behind Boehringer Ingelheim but above big names such as Biogen....
...Boehringer is also entitled to some further payments that are pegged to the drug’s success, Ms Whitehead said....
...First in line will be flibanserin, a drug originally submitted to the FDA by Boehringer Ingelheim of Germany and rejected in 2010, on the grounds that its benefits did not outweigh side-effects....
International Edition